KaloCyte Closes Investment from New York Blood Center
July. 20th, 2022
KaloCyte, Inc., a developer of bio-inspired red blood cell substitute ErythroMer™, announced it has closed an investment from New York Blood Center, Inc. (NYBC).
KaloCyte, Inc., a developer of bio-inspired red blood cell substitute ErythroMer™, announced it has closed an investment from New York Blood Center, Inc. (NYBC).